0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$50.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
Hexarelin produces the highest magnitude GH secretagogue receptor activation among characterized GHRPs, generating GH pulse dynamics 2–3 times greater than GHRP-2 or GHRP-6 in preclinical experimental models. This maximal activation profile enables researchers to investigate ghrelin receptor occupancy ceiling parameters, dose-response plateau dynamics, and receptor desensitization kinetics under high-potency secretagogue exposure conditions. Comparative study designs employing Hexarelin alongside lower-potency GHRPs such as Ipamorelin support systematic characterization of potency-dependent differences in downstream GH pathway signaling marker expression and receptor sensitivity response patterns.
Beyond ghrelin receptor-mediated GH secretagogue activity, Hexarelin binds CD36 receptors expressed in cardiac tissue experimental models, initiating downstream cardioprotective signaling pathway dynamics independent of GH pathway activation. Research examining CD36-mediated anti-ischemic signaling marker expression, anti-inflammatory pathway endpoint activity, and anti-fibrotic molecular marker characterization in cardiac tissue models uses Hexarelin as a dual-mechanism reference compound. This GH-independent CD36 binding activity enables multi-arm study designs investigating simultaneous ghrelin receptor and CD36 receptor co-activation pathway dynamics and their respective downstream molecular marker contributions in preclinical cardiovascular signaling research.
Novera supplies Hexarelin 5mg sourced from USA GMP-certified manufacturing facilities, independently verified to approximately 99% purity by third-party COA documentation. Each vial confirms peptide sequence identity, purity grade, and batch-specific quality control data — providing research laboratories with consistent, pharmaceutical-grade ultra-potent GHRP material for advanced secretagogue pharmacology and CD36 receptor signaling pathway research.
Hexarelin 5mg is suited for research teams and signaling pharmacology laboratories investigating ultra-potent GH secretagogue receptor activation dynamics, ghrelin receptor occupancy ceiling effects, and receptor desensitization kinetics in controlled preclinical models. Scientists examining maximum GH pulse generation mechanics, dose-response ceiling characterization, and downstream IGF-1 and GH pathway signaling marker expression will find Hexarelin relevant to high-intensity secretagogue pharmacology study designs. Research programs requiring a structurally defined ultra-potent GHRP reference compound for comparative receptor pharmacology investigations alongside more selective GHRPs such as Ipamorelin or GHRP-2 benefit from Hexarelin’s distinct maximal-activation receptor profile.
Laboratories studying CD36 receptor binding dynamics in cardiac tissue experimental models — and the downstream cardioprotective signaling pathway markers associated with GH-independent CD36 engagement — will find Hexarelin uniquely suited to dual-mechanism receptor pharmacology study designs examining simultaneous ghrelin receptor and CD36 receptor co-activation. Novera supplies Hexarelin 5mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for purity and sequence identity to approximately 99%.
Hexarelin supports preclinical investigation of maximal ghrelin receptor occupancy dynamics, GH pulse ceiling characterization, and receptor desensitization onset kinetics under sustained ultra-potent secretagogue exposure conditions. Researchers quantifying the temporal relationship between high-potency receptor activation, downstream GH pathway marker response magnitude, and receptor sensitivity attenuation use Hexarelin as a primary reference compound for GHRP ceiling-effect and desensitization pharmacology study designs. Cycling protocol investigations examining receptor resensitization dynamics following withdrawal periods contribute to mechanistic characterization of ghrelin receptor plasticity under maximal-activation exposure conditions.
Laboratories studying GH secretagogue-mediated downstream signaling use Hexarelin to quantify IGF-1 pathway marker activity, GH-dependent anabolic signaling cascade expression, and downstream metabolic regulatory marker dynamics in preclinical experimental models. Multi-arm protocols comparing ultra-potent Hexarelin-mediated downstream signaling endpoint profiles with those produced by more selective GHRPs support mechanistic characterization of potency-dependent differences in GH pathway molecular marker response patterns across tissue and cell line experimental systems.
Hexarelin’s GH-independent CD36 receptor binding activity enables investigation of cardiac tissue CD36 occupancy dynamics, downstream anti-ischemic signaling pathway marker expression, and cardioprotective molecular endpoint characterization in preclinical cardiovascular model systems. Research examining CD36-mediated anti-inflammatory and anti-fibrotic signaling cascade dynamics uses Hexarelin as a mechanistically distinct reference compound for cardiovascular receptor pharmacology study designs. Multi-arm protocols isolating CD36-mediated signaling contributions from concurrent ghrelin receptor-mediated GH pathway activity support systematic dissection of each receptor system’s downstream molecular marker contributions.
Hexarelin’s maximal GH secretagogue activation profile enables multi-arm comparative study designs examining how ultra-potent ghrelin receptor activation produces different downstream signaling pathway marker patterns relative to more selective GHRPs such as Ipamorelin or GHRP-2. Research quantifying potency-dependent molecular endpoint differences across GH pathway markers, receptor desensitization kinetics, and downstream IGF-1 signaling cascade dynamics contributes to mechanistic understanding of secretagogue potency-dependent receptor pharmacology across shared downstream pathway systems.
Reconstitute lyophilized Hexarelin 5mg with sterile bacteriostatic water using standard sterile laboratory technique. Reconstitution volume should be determined based on the target experimental working concentration specified by the study design. Research protocols investigating receptor desensitization and resensitization dynamics typically employ defined cycling intervals with documented withdrawal periods; each reconstitution step should be recorded in accordance with institutional research record-keeping standards. Use calibrated laboratory equipment throughout all preparation steps.
Store lyophilized peptide at 2–8°C, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C; reconstituted peptide remains stable for approximately 2–4 weeks under appropriate storage conditions. This product does not require cold-chain shipping, but immediate refrigeration upon receipt is recommended to preserve ultra-potent GHRP peptide integrity throughout the protocol period. Each vial supplied by Novera includes COA documentation and handling guidance.
Preclinical GH secretagogue pharmacology studies using Hexarelin typically incorporate cycling intervals of 2–4 weeks active exposure followed by defined withdrawal periods to characterize receptor desensitization and resensitization kinetics systematically. Initial measurable downstream GH pathway and CD36 signaling marker responses in preclinical models may be observed within 2–4 weeks of protocol initiation. Monitor ghrelin receptor pathway activity markers, downstream IGF-1 signaling cascade dynamics, CD36-mediated cardioprotective pathway markers, and receptor sensitivity indicators at defined experimental intervals throughout the observation period, in accordance with institutional laboratory standards.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic peptide formulated in mid-range 10mg quantity for cellular migration studies and peptide actin-binding research in controlled laboratory environments.
Research-grade cathelicidin-derived peptide formulated for experimental immune-related research in controlled laboratory environments.
Research-grade decapeptide signaling molecule formulated for experimental peptide pathway research in controlled laboratory environments.
Research-grade synthetic dual-peptide formulation combining amylin analog and GLP-1 receptor agonist for dual-mechanism pathway studies and combination peptide research in controlled laboratory environments.
A synthetic aromatic-cationic tetrapeptide studied for selective inner mitochondrial membrane localization, cardiolipin binding dynamics, and oxidative phosphorylation pathway marker activity in controlled in-vitro and preclinical models.
